Herbert Y. Meltzer

Original Research

Original Research

Original Research

Letter to the Editor

Original Research

Original Research

Original Research

Original Research

Letter to the Editor

Original Research

Worldview of Psychiatry

Consensus Statement

Original Research

Consensus Statement

Herbert Y. Meltzer

Adverse Events Related to Olanzapine

Aripiprazole for Treatment-Resistant Schizophrenia: Results of a Multicenter, Randomized, Double-Blind, Comparison Study Versus Perphenazine

Assessing Cardiovascular Risks Versus Clinical Benefits of Atypical Antipsychotic Drug Treatment

Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial

Conclusions: Side Effects of Antipsychotic Medications

A Double-Blind Study of Combination of Clozapine With Risperidone in Patients With Schizophrenia: Effects on Cognition

Drs. Meltzer and Jayathilake Reply

Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

Genetic Dissection of Atypical Antipsychotic-Induced Weight Gain: Novel Preliminary Data on the Pharmacogenetic Puzzle

Introduction: Cardiovascular and Metabolic Risks Associated With Schizophrenia and Antipsychotic Drug Treatment

Introduction: Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance

Introduction: Weight Gain: A Growing Problem in Schizophrenia Management

Low-Dose Loxapine in the Treatment of Schizophrenia: Is It More Effective and More "Atypical" Than Standard-Dose Loxapine?

A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

Outcome in Schizophrenia: Beyond Symptom Reduction

Putting Metabolic Side Effects Into Perspective: Risks Versus Benefits of Atypical Antipsychotics

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

Reply to Aripiprazole and Perphenazine: No Difference

The Rise of Psychopharmacology and the Story of CINP

Schizophrenia in Children and Adolescents

Schizophrenia in a Molecular Age: Review of Psychiatry, vol. 18

Suicide in Schizophrenia, Clozapine, and Adoption of Evidence-Based Medicine

Suicide and Schizophrenia: Clozapine and the InterSePT Study

Suicide in Schizophrenia: Risk Factors and Clozapine Treatment

Worldview of Psychiatry

Sulfotransferase 4A1 Haplotype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia

Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Brief Report

A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine: Efficacy and Safety

Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles